|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Aug 13, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Investor receivable | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total investor receivable | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Prepaid expenses, long-term | ||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||
| Operating right of use asset | ||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||
| Goodwill | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Current liabilities | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Accrued expenses | ||||||||||||||||||
| Notes payable, net of debt discount of $569,907 | ||||||||||||||||||
| Notes payable | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total notes payable | ||||||||||||||||||
| Operating lease liability, current | ||||||||||||||||||
| Subscription agreement liability – Related Party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total subscription agreement liability – Related Party | ||||||||||||||||||
| Contingent warrant liabilities | ||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||
| Due to Shareholders | ||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Note payable, net of current portion | ||||||||||||||||||
| Subscription agreement liability – related party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total subscription agreement liability – related party | ||||||||||||||||||
| Subscription agreement liability, long-term related party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total subscription agreement liability, long-term related party | ||||||||||||||||||
| Pension benefit obligation | ||||||||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||||||
| Deferred tax liability, net | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Series C Redeemable Preferred Stock, $0.00001 par value, 10,000 shares authorized, 7 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Series B Convertible Redeemable Preferred stock | ||||||||||||||||||
| Series C Redeemable Preferred Stock | ||||||||||||||||||
| Total series C Redeemable Preferred Stock, $0.00001 par value, 10,000 shares authorized, 7 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||
| Common stock, $0.00001 par value, 250,000,000 shares authorized at June 30, 2026 and December 31, 2025; 3,793,676 and 31,201 shares issued at June 30, 2026 and December 31, 2025, respectively; 3,793,673 and 31,198 shares outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Treasury stock, at cost; 12,934 shares of common stock at December 31, 2024 and 2023 | ||||||||||||||||||
| Treasury stock, at cost; 3 shares of common stock at June 30, 2026 and December 31, 2025 | ||||||||||||||||||
| Due from shareholders | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||
| Total Onconetix, Inc. stockholders’ equity (deficit) | ||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||
| Total liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||||
Loading...